Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2002
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Key products include EPOGEN, Aranesp, NEUPOGEN, and Neulasta. The report covers the three and six months ended June 30, 2002, and includes significant subsequent events regarding the acquisition of Immunex Corporation.
Key Financial Metrics
| Financial Metric (in millions) | Three Months Ended June 30, 2002 |
Six Months Ended June 30, 2002 |
|---|---|---|
| Total Revenues | $1,249.1 | $2,257.6 |
| Net Income | $412.4 | $753.3 |
| Diluted Earnings Per Share | $0.38 | $0.70 |
| Operating Cash Flow | N/A | $1,124.6 |
| Cash and Cash Equivalents | $2,905.0 | $2,905.0 |
| Long-Term Debt | $3,054.8 | $3,054.8 |
| Cost of Sales Margin | 11.8% | 11.6% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 26.5% for the three months and 19.6% for the six months ended June 30, 2002, compared to the same periods in 2001. Product sales grew 30% (quarterly) and 22% (year-to-date), driven by demand for EPOGEN, Aranesp, and the launch of Neulasta.
- Profitability: Net income rose 28% for the quarter and 20% for the six-month period. Operating income increased 25.7% (quarterly) and 18.1% (year-to-date).
- Expense Increases: Selling, general, and administrative (SG&A) expenses increased 42% (quarterly) and 34% (year-to-date) due to higher marketing costs for new product launches. R&D expenses increased 12% (quarterly) and 5% (year-to-date).
- Debt Structure: Long-term debt increased significantly from $223.0 million (Dec 31, 2001) to $3,054.8 million (June 30, 2002) following the issuance of $3.95 billion in 30-year zero-coupon senior convertible notes in March 2002.
- Liquidity: Cash and cash equivalents surged from $689.1 million to $2,905.0 million, bolstered by the convertible note issuance and strong operating cash flow.
Guidance, Outlook, and Risks
Subsequent Event: Immunex Acquisition
On July 15, 2002, Amgen completed the acquisition of Immunex Corporation for a total value of approximately $17.7 billion (cash and stock). This transaction is not reflected in the financial statements but will significantly impact future operations.
Financial Outlook
- Revenue Drivers: Future growth is expected from Aranesp, Neulasta, and Enbrel (acquired via Immunex).
- Expense Impact: R&D and SG&A spending are expected to accelerate in the second half of 2002 due to the Immunex acquisition.
- One-Time Charges: Amgen expects to record a one-time non-cash expense of approximately $2.4 billion in the quarter ending September 30, 2002, related to the write-off of acquired in-process R&D. Additionally, annual amortization of acquired intangible assets is estimated at $260 million (net of tax).
- Capital Expenditures: Spending is expected to be significantly higher due to capital requirements for acquired facilities.
Risks and Contingencies
- Supply Constraints: Enbrel sales are currently constrained by supply limits from third-party manufacturer Boehringer Ingelheim Pharma KG. Amgen is preparing its own Rhode Island facility and has agreements with Genentech and Wyeth to increase capacity.
- Reimbursement: Sales depend heavily on third-party payor reimbursement (e.g., Medicare, Medicaid). Changes in reimbursement rates could materially affect sales.
- Legal Proceedings: Amgen is involved in patent litigation (e.g., Transkaryotic Therapies, Aventis, Genentech) and Average Wholesale Price (AWP) litigation. The company believes these will not have a material adverse effect on annual financial statements.
Key Facts for Investor Verification
- Immunex Integration: Verify the timeline and financial impact of the $17.7 billion Immunex acquisition, specifically the $2.4 billion in-process R&D write-off expected in Q3 2002.
- Convertible Notes: Review the terms of the $3.95 billion zero-coupon convertible notes issued in March 2002, including the conversion rate (8.8601 shares per note) and potential dilution.
- Enbrel Supply Chain: Monitor the status of FDA approval for Amgen's Rhode Island manufacturing facility and the capacity ramp-up with Genentech and Wyeth to ensure Enbrel supply meets demand.
- Product Launches: Track the commercial performance of Neulasta (launched April 2002) and Aranesp (new indications approved in EU and US) as primary growth drivers.
- Legal Exposure: Monitor developments in the AWP litigation and patent disputes regarding erythropoietin and G-CSF products.